PCI Biotech : Remuneration Report 2022
Remuneration Report 2022 Introduction PCI Biotech is a biopharmaceutical company utilising its innovative photochemical... | May 4, 2023
Stay updated with breaking news from Ludovic Robin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Remuneration Report 2022 Introduction PCI Biotech is a biopharmaceutical company utilising its innovative photochemical... | May 4, 2023
Oslo (Norway), 31 August 2022 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first-half year 2022 results. Please find enclosed the report and presentation. Highlights Corporate*The
Oslo (Norway), 11 May 2022 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2022 results. Please find enclosed the report and presentation. Highlights fimaVacc*The
PCI Biotech Holding ASA: PCI Biotech fourth quarter and preliminary full year 2020 results Highlights Chem *The first Asian patient was enrolled in the RELEASE study in South Korea in October, less than three months after opening of the first study site in Asia. All the nine planned study sites in South Korea and Taiwan have been opened, with initial good screening activity *Several initiatives have been implemented in the RELEASE study to recoup long-term recruitment projections. Besides going into Asia, the most important initiatives are the protocol amendment made to expand the eligible pa...